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ABSTRACT  15 
This study aimed to develop advanced biomaterial polysaccharide based dressings to manage 16 
pain associated with infected chronic leg ulcers in older adults. Composite carrageenan (CARR) 17 
and hyaluronic acid (HA) dressings loaded with lidocaine (LID) and AgNPs were formulated as 18 
freeze-dried wafers and functionally characterized for porous microstructure (morphology), 19 
mechanical strength, moisture handling properties, swelling, adhesion and lidocaine release. 20 
Antimicrobial activity of AgNPs was evaluated (turbidity assay) against Escherichia coli, 21 
Pseudomonas aeruginosa and Staphylococcus aureus whilst cell viability studies (MTT) was 22 
performed on normal adult human primary epidermal keratinocyte cells. The wafers were soft, 23 
flexible and elegant in appearance. HA affected the wafer structure by increasing the resistance 24 
to compression but still possessed a balance between toughness and flexibility to withstand 25 
normal stresses and prevent damage to newly formed skin tissue respectively. Water uptake was 26 
influenced by HA, whilst equilibrium water content and LID release were similar for all the 27 
formulations, showing controlled release up to 6 h. AgNPs loaded CARR/HA wafers were 28 
effective in inhibiting the growth of both Gram positive and Gram negative bacteria. MTT assay 29 
showed evidence that the AgNPs/ LID loaded wafers did not interfere with cell viability and 30 
growth. CARR/HA wafers seem to be a promising system to simultaneously deliver LID and 31 
AgNPs, directly to infected chronic leg ulcers.  32 
 33 
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1. INTRODUCTION 37 
  Pain is very common in leg ulcer patients with about 1% of the Western population 38 
estimated to suffer from chronic leg ulcers (CLUs) (O’Meara et al., 2012) with 17-65% of these 39 
experiencing severe pain (Philips et al., 1994). Leg ulcers are common in older adults due to risk 40 
factors including immobility and venous disease (Simon et al., 2004) and affect up to 2% of the 41 
population over 80 years old (Petherick et al., 2013). Pain, together with leaking exudate, odor, 42 
restricted mobility and sleep disturbance may be particularly challenging and distressing for 43 
patients and have a negative impact on all aspects of daily living, causing depression, anxiety 44 
and social isolation (Green et al., 2014). Furthermore, CLUs present a significant socio-45 
economic burden for health systems, with up to 3% of the entire healthcare budget, spent on 46 
managing CLUs (Augustin et al., 2014; Posnett et al., 2008).  47 
  In CLUs, the wound is stuck in a continuous inflammation cycle, which coupled with 48 
local factors (e.g. ischemia, infection and maceration) and underlying pathologies (e.g. diabetic 49 
neuropathy, peripheral vascular disease), causes background pain. Pain also results from repeated 50 
tissue insults caused by physical trauma, but the most common cause of wound pain is during 51 
dressing change, debriding, and wound cleansing. Multilayer compression bandaging has been 52 
identified as the gold standard in the treatment of venous leg ulcers (Harding et al., 2015), but 53 
exudate control is a critical factor for its success. For this reason, health professionals would 54 
welcome a dressing that deals with absorption challenges and help pain management, 55 
particularly during dressing changes (Jorgensen et al., 2006). 56 
  Wound infection contributes to pain by triggering a continuous inflammatory response 57 
through the release of inflammatory mediators, stimulating the production of enzymes and free 58 
radicals, which can cause tissue damage (White, 2009). The consequent pain-related stress leads 59 
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to reduced immune response to infection and stimulation of pro-inflammatory cytokine 60 
production in the wound (Glaser et al., 1999). Therefore, treatment of pain and infection should 61 
be equally prioritized (Boateng & Catanzano, 2015). CLUs are particularly at risk of infection 62 
due to high microbial bioburden (White et al., 2006) and the inability of leukocytes for 63 
phagocytosis and intracellular killing of microorganisms (Oncul et al., 2007). Different 64 
antibiotics have been used against wound infections, but the development of resistance has 65 
highlighted the need for alternative solutions. Recently, silver nanoparticles (AgNPs) have been 66 
recognized as optimal candidates for overcoming wound infections and due to their broad-67 
spectrum antimicrobial characteristics, have been widely used in CLU (Rizzello & Pompa, 68 
2014). The use of AgNPs-containing dressings in the treatment of infected wounds has been 69 
explored as a way to reduce risk of infection in the wound area and avoid delays in wound 70 
closure (Boateng et al., 2008; 2015; Hebeisha et al., 2014). However, as noted earlier, wound 71 
infection is also a cause of inflammation and pain so the delivery of AgNPs could be an indirect 72 
way to reduce wound pain in CLUs. 73 
 Natural polysaccharides (e.g. chitosan and cellulose) have been reported by several authors as 74 
delivery systems for AgNPs for treating infected wounds (El-Naggar et al., 2016; Ganest et al., 75 
2016; Ding et al., 2017; Singla et al., 2017). Carrageenan (CARR) and hyaluronic acid (HA) are 76 
two very promising natural polysaccharides for wound dressing application due their good 77 
biocompatibility, structural properties and biological activity (Boateng et al., 2013, 2015). CARR 78 
is a natural carbohydrate polymer, extracted from intracellular matrix of red seaweeds, widely 79 
used in the food industry for its excellent gelling capacity and the three commercially relevant 80 
grades are kappa (κ), iota (ι), and lambda (λ). All CARRs are high-molecular-weight 81 
polysaccharides made up of repeating galactose units and 3,6 anhydrogalactose (A), joined by 82 
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alternating α-1,3 and β-1,4 glycosidic (G) linkages. The main differences between kappa, iota, 83 
and lambda CARRs are number and position of the ester sulfate groups on the repeating 84 
galactose units and the molecular weight (Cunha & Grenha, 2016). κ-CARR has an ester sulfate 85 
content of 25 - 30%, which imparts excellent film and gel forming capacity and together with 86 
good biocompatibility, indicate that κ-CARR could be a versatile biomaterial for drug delivery. 87 
Furthermore, κ-CARR exhibits immune and blood coagulation activities useful in tissue 88 
engineering and wound healing (Cunha & Grenha, 2016; Liu et al., 2015; angestuti & Kim, 89 
2014). During heating CARR first exists as random coil but the chains reorganize themselves as 90 
double helices when cooled (Cunha and Grenha, 2015). In general, CARR lends itself to a 91 
variety of applications to modify drug release and improve drug dissolution, and recently, our 92 
group proposed κ-CARR based formulations for buccal mucosa drug delivery (Kianfar et al., 93 
2014; Kianfar et al., 2013), and as dressings for drug delivery to wounds (Boateng et al., 2013, 94 
2015). 95 
 Hyaluronic acid (HA) is a long-chain linear glycosaminoglycan consisting of repeating 96 
units of (β 1-4)-d-glucuronic acid and (β 1-3)-N-acetyl-d-glucosamine found naturally in the 97 
body and acts as a structural component of the extracellular matrix (ECM) and mediator of 98 
various cellular functions. HA is involved in each phase of wound healing increasing 99 
keratinocyte migration and proliferation and facilitating transport of nutrients and waste products 100 
(Dicker et al., 2014; Frenkel, 2012). HA was found to accelerate wound healing in both in vitro 101 
(Catanzano et al., 2015) and in vivo (Foschi et al., 1990; King et al., 1991) models, and 102 
accelerated skin wound healing in patients affected by different chronic wounds (Voigt & Driver, 103 
2012).  104 
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 The use of local anesthetic in the treatment of chronic wound pain can only give transitory 105 
relief in patients that are constantly in pain, whereas the treatment of wound infection alone has 106 
no effect on wound acute pain. For these reasons, we hypothesized that a composite 107 
polysaccharide dressing comprising CARR and HA, loaded with a local anesthetic and AgNPs 108 
could be very beneficial for the patients, acting directly on pain associated with CLUs as well as 109 
deal with infection which one of the main causes of chronic inflammatory pain, consequently 110 
enhancing wound healing and improving patient well-being. For this purpose, we present an 111 
innovative and convenient multi-disciplinary approach based on composite polymeric wafers 112 
capable of simultaneous delivery of an anesthetic drug, lidocaine (LID) and AgNPs. Wafers were 113 
formulated from gels combining different ratios of CARR and HA, taking advantage of the 114 
beneficial and well recognized properties of HA in the wound healing process. Different amounts 115 
of LID and AgNPs were tested to evaluate the antimicrobial activity on Gram-negative and 116 
Gram-positive bacteria and in vitro cytotoxicity in normal adult human primary epidermal 117 
keratinocyte cell lines. 118 
 119 
  120 
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2 MATERIALS AND METHODS 121 
2.1 Materials 122 
Low viscosity κ-carrageenan (Gelcarin GP 812 NF, molecular weight <100 kDa, 25% ester 123 
sulfate and 34% 3,6-AG, stable at pH above 3.8) was obtained from FMC Biopolymer Corp 124 
(Princeton, NY, USA). Sodium hyalorunate Hyasis® (mean molecular weight 0.8 MDa, intrinsic 125 
viscosity 15dL/g) was a kind gift from Novozyme (Bagsvaerd, Denmark). Silver nanoparticles 126 
(AgNPs) was provided as solution in water (10,000 ppm) from Clusternanotech Ltd. (UK). 127 
Acetonitrile (HPLC grade), ethanol (laboratory grade), yeast extract, tryptone, 3-(4,5-128 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and streptomycin sulphate (STP) 129 
were all obtained from Fisher Scientific (Leicestershire, UK). Lidocaine hydrochloride 130 
monohydrate (LID), bovine serum albumin (BSA), and all other chemicals were purchased from 131 
Sigma Aldrich (Gillingham, UK). Media, sera, and antibiotics for cell cultures were from ATCC 132 
(American Type Culture Collection, USA). Deionized ultra-filtered water was used throughout 133 
this study. 134 
 135 
2.2 Preparation of CARR/HA composite wafers 136 
CARR and CARR/HA wafers were prepared by dispersing the polymers in stirred hot 137 
water (70°C) until completely dissolved to obtain an aqueous polymeric solution (2% w/v) made 138 
of only CARR and blends of CARR with HA in different weight ratios (90/10, 70/30, 50/50, 139 
labelled as CARR/HA10, CARR/HA30 and CARR/HA50 respectively. For drug-loaded wafers, 140 
LID (10% w/w based on total polymer weight) and AgNPs (100 – 750 μg/wafer) were dissolved 141 
directly in the polymeric solution. Solutions were cast in a 24-well plates (1 ml, well size: 15 mm 142 
diameter, 20 mm height) and lyophilized using an automated cycle on a Virtis Advantage XL 70 143 
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freeze dryer (Biopharma Process Systems, Winchester, UK) to form circular disks. The freeze-144 
drying process involved initially cooling the samples from room temperature to −50°C (8 h) and 145 
heated during the primary drying phase (50 mTorr, −25°C) for 24 h to sublimate the ice, 146 
followed by 7 h of secondary drying (10mTorr, 20°C) to remove free water. The wafers were 147 
removed from the dish and kept in desiccators over calcium chloride at room temperature till 148 
required.  149 
 150 
2.3 Physical and analytical characterization 151 
The surface morphology of the CARR/HA wafers was analyzed using scanning electron 152 
microscopy (SEM). Samples were cut into small, thin pieces, placed on Agar Scientific double-153 
sided carbon adhesive tape on Agar Scientific G301 aluminium stub and coated with gold using 154 
Sputter Coater (Edwards 188 Sputter Coater S1508) evaporator for 90 - 120 s. Images were 155 
obtained using a Hitachi SU8030 (Hitachi High-Technologies, Krefeld, Germany) scanning 156 
microscope under low vacuum at 5.0 kV accelerating voltage. 157 
 The average porosity of wafers was determined by a fluid replacement method. The 158 
geometrical volume (Vs) of the wafers (n = 5) was calculated by measuring diameter and height, 159 
and the pore volume (Vp) was measured by ethanol displacement. The dry wafer was weighed 160 
(W0) and immersed in absolute ethanol at room temperature, and placed in a degasser for 10 min 161 
to remove air bubbles. After wiping gently with a filter paper, samples were weighed 162 
immediately (We). The porosity of the wafers was calculated using equation 1: 163 
 164 
Porosity =
𝑉𝑝
𝑉𝑠
 𝑋 100 =  
𝑊𝑒− 𝑊0
𝜌𝑒𝑉𝑠
 𝑋 100      [Equation 1] 165 
 166 
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where ρe represents the density of ethanol (0.789 g/cm3).  167 
The apparent density (ρ) of the sponge was calculated using equation 2:  168 
 169 
𝜌 =
𝑊0
𝑉𝑠
           [Equation 2] 170 
 171 
 For water retention rate, wafer was soaked in water for 20 min, carefully removed, gently 172 
wiped on tissue paper to remove the excess water and placed in a centrifuge tube equipped with a 173 
mesh bottom, centrifuged at 500 rpm for 2 min and the wet weight recorded. An average value of 174 
five replicates (n = 5) for each sample was taken. Water retention rate (WR) was calculated with 175 
equation 3: 176 
 177 
WR =
Mh−Md
Md
 X 100         [Equation 3] 178 
 179 
Where Mh is the weight (g) of the wafer after centrifugation, and Md is the initial dry weight (g).  180 
 The residual moisture in the wafers was estimated using thermogravimetric analysis 181 
(TGA) (Thermal Advantage 2950, TA Instruments, Crawley UK). Samples (n = 4) weighing 182 
between 3 and 6 mg were placed in a previously tared 70 μL aluminium crucible and heated at 183 
10°C/min from ambient temperature to 200°C under a constant stream of dry nitrogen. The 184 
weight loss was plotted against temperature and percentage residual moisture was estimated from 185 
the second derivative plot using TA Universal Analysis 2000 software. 186 
 A Fourier transform infrared spectrometer (FT-IR) equipped with a ZnSe attenuated total 187 
reflectance (ATR) crystal accessory (Nicolet 8700 FTIR spectrometer, Thermo Fisher Scientific, 188 
Surrey, UK) was used to investigate interaction between CARR and HA during formulation and 189 
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presence of unmodified HA. Wafers and starting materials, were placed on the ATR crystal and 190 
pressed with a pressure clamp to allow optimal contact between the material and the crystal and 191 
FT-IR spectra were collected over 4000–400 cm−1 using a resolution of 1 cm−1.  192 
2.4 Swelling studies 193 
The percentage swelling ratio was determined by placing the wafers in simulated wound fluid 194 
(SWF, CaCl 0.02 M, NaCl 0.4 M, Trizma base 0.4 M, BSA 2% w/v). The initial weight of each 195 
wafer was recorded and completely immersed in 5 mL of SWF (37°C). Samples were carefully 196 
taken out, excess SWF removed by carefully blotting with tissue paper, weighed and re-197 
immersed in SWF. Weights were recorded at intervals of 1 h up to 6 h and every 24 h from then 198 
onwards until equilibrium was established and SWF replaced after every weight measurement. 199 
The percentage swelling ratio (SR %) was calculated using equation 4: 200 
 201 
𝑆𝑅% =  
𝑊−𝑊0
𝑊0
 ×  100        [Equation 4] 202 
 203 
Where W is the mass of the swollen sample and W0 is the mass of the initial dry sample. The  204 
equilibrium water content (EWC) per cent was calculated using equation 5: 205 
 206 
EWC (%) =  
𝑊𝑒 − 𝑊0
𝑊𝑒
 × 100        [Equation 5] 207 
 208 
Where We is the mass of the swollen sample at equilibrium. 209 
 210 
2.5 Mechanical hardness and in vitro wound adhesive properties 211 
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Mechanical properties (resistance to deformation and ease of recovery) of the freeze-dried wafers 212 
were investigated by compressing on a Texture Analyzer (TA) (Stable Microsystems Ltd., 213 
Surrey, UK) equipped with 5 kg load cell and Texture Exponent-32® software program. A 6 mm 214 
cylindrical stainless steel probe was used in compression mode. Wafers (n = 5) were compressed 215 
at three different locations to a depth of 2 mm at a speed of 1 mm/s using a trigger force of 0.001 216 
N to determine the effects of HA on the resistance to deformation (‘hardness’).  217 
 In vitro wound adhesion was performed using the same apparatus but in tension mode. 218 
Samples (n = 5) were attached to a 75 mm diameter probe using double-sided adhesive tape. A 219 
6.67% w/v gelatin solution was allowed to set as solid gel in a Petri dish (diameter 88 mm) and 220 
0.5 mL of SWF spread over the surface to simulate a moist wound (Boateng et al., 2013, 2015). 221 
The probe, lined with wafer, was set to approach the model wound surface with the following 222 
conditions: pre-test speed - 0.5 mm/s; test speed - 0.5 mm/s; post-test speed - 1.0 mm/s; applied 223 
force - 0.01 N; contact time - 60.0 s; trigger type - auto; trigger force - 0.05 N and return distance 224 
of 10.0 mm (Pawar et al., 2014). The maximum force required to detach the wafer on the upper 225 
probe (stickiness) from the model wound surface, known as the peak adhesive force (PAF), total 226 
work of adhesion (WOA) represented by the area under the force versus distance curve, and 227 
cohesiveness, defined as the distance travelled by wafer till detached, were calculated using the 228 
Texture Exponent-32® software. 229 
 230 
2.6 In vitro LID release 231 
In vitro release of LID from CARR and CARR/HA wafers (n = 3) was evaluated in SWF 232 
at 37°C under gentle shaking and SWF (11 mL) was in contact with the wafers only by their 233 
lower surface. The SWF was prepared without BSA to avoid blocking of the HPLC column. At 234 
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set times, 1.0 mL of release medium was withdrawn, replaced by the same amount of fresh SWF 235 
and analyzed. Concentration of LID within the wafers and amount released at each time point 236 
was determined by HPLC using an Agilent 1200 HPLC system (Agilent Technologies, Cheshire, 237 
UK) equipped with a Chemstation® software program. The stationary phase was a Gemini C18 238 
column (250 mm x 4.6 mm, 300 Å) (Phenomenex, USA), mobile phase comprised 5% acetic 239 
acid in water (pH 3.4) and acetonitrile in the ratio of 80:20 (v/v) at flow rate of 1.0 mL/min, 240 
injection volume was 20 µL and detection wavelength at 262 nm. The linearity of the response 241 
was verified over a LID concentration range of 5 - 500 μg/ml (R2 = 0.997). 242 
 243 
2.7  In vitro cytotoxicity  244 
Cell viability studies were performed on normal adult human primary epidermal 245 
keratinocyte cells (ATCC PCS-200-011). The cells were cultured in cell culture flasks using a 246 
complete culture medium consisting of dermal cell basal medium (ATCC® PCS-200-030) plus 247 
one keratinocyte growth kit (ATCC® PCS-200-040) containing bovine pituitary extract (BPE), rh 248 
TGFα, L-glutamine, hydrocortisone hemisuccinate, insulin, epinephrine and apotransferrin and 249 
supplemented with 10 IU/mL of penicillin, and 10 μg/mL of streptomycin. Cultures were 250 
maintained in humidified atmosphere of 95% air and 5% CO2 at 37°C. The MTT (3-(4,5-251 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay was used to 252 
evaluate the cell viability when in contact with the wafers (International Standardization 253 
Organization, 1992) (details in supplementary information S1). 254 
  255 
2.8 Antimicrobial assay 256 
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The antimicrobial activity of AgNPs-loaded wafers was tested on E. coli (ATCC 25922), 257 
P. aeruginosa (ATCC 10145) and S. aureus (ATCC 29213). Wafers containing 100 μg 258 
(CARR/AgNPs100), 250 μg (CARR/AgNPs250), 500 μg (CARR/AgNPs500), and 750 μg 259 
(CARR/AgNPs750) each of AgNPs were used. Bacterial suspensions were prepared by taking 2-3 260 
fresh colonies grown on Luria Bertani (LB) agar plates and suspended in sterile LB broth with no 261 
sodium chloride (Tryptone 10 g/L, yeast extract 5 g/L). The turbidity was adjusted to 0.5 262 
McFarland standard (∼108 cfu/mL) and then diluted to 106 cfu/mL (representing highly infected 263 
chronic wounds) with fresh LB broth. Equally weighed samples were placed in sterile plastic 264 
tubes, submerged with 10 mL of bacterial suspension, and incubated at 37°C in a shaking 265 
incubator (100 rpm/min). Absorbance (A) at 580 nm of the bacterial suspension incubated with 266 
samples (n = 3) at different time points (6, 24 and 48 h) were noted and difference in turbidity 267 
was visually analyzed. 400 μL of streptomycin sulfate solution (1 mg/mL), and unloaded wafers 268 
were used as positive and negative controls respectively.  269 
 270 
2.9 Statistical analyses 271 
Statistical analyses were undertaken using GraphPad Prism®, version 6.00 (GraphPad Software, 272 
La Jolla California USA, www.graphpad.com) and data compared using a Student's t-test and a 273 
one-way ANOVA where relevant, with a Bonferroni post-test (parametric methods). 274 
 275 
3 RESULTS  276 
3.1 Formulation development 277 
Freeze drying is a simple way to produce porous sponge-like dressings, useful in medium to 278 
high exuding wounds (Matthews et al., 2005). Composite CARR/HA wafers possessed a smooth 279 
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surface with uniform mass, texture and toughness. All formulations were elegant with no visible 280 
cracks but the balance between flexibility and toughness changed depending on HA 281 
concentration.  282 
 283 
3.2 Wafer characterization 284 
Representative SEM images of wafers are shown in Figure 1, showing porous 285 
interconnecting network of polymeric strands having irregular and hexagonal shaped pores with 286 
thin strands. CARR wafers formed an interconnecting network, with an average pore diameter of 287 
50 μm and an open cell structure with hexagonal shaped pores. Addition of HA resulted in 288 
smaller pore sizes with an average pore diameter between 10 and 30 μm. HA has an important 289 
role in porosity development and wafers with higher HA amount showed relatively smaller sized 290 
pores and a more irregular matrix structure. Such changes in microstructure can affect other 291 
physical properties such as ‘hardness’ and hydration (Pawar et al., 2014).  292 
 293 
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 294 
Figure 1: Representative SEM micrographs of CARR and CARR/HA wafers showing differences in porous 295 
microstructure with different amounts of HA (x40, scale bar = 1mm). 296 
 297 
 The porosity and water handling properties for the various wafers are summarized in 298 
Table 1. CARR wafers with more open and ordered pores and solid internal structure, had a 299 
water absorption > 3700 g water per 100 g of wafer, however addition of HA caused variation in 300 
all the physical properties. Both the porosity values, and apparent density of the wafers were 301 
influenced by HA, which made them more porous and less dense, therefore decreasing the water 302 
absorption. The water retention capacity was highest for CARR/HA50 and generally higher in 303 
CARR/HA wafers compared to CARR wafer, due to the higher hydrophilic character of HA 304 
(Tool, 2004) which also resulted in slightly higher residual moisture content for CARR/HA 305 
wafers ranging from 17.00 ± 0.57% (CARR wafer) to 18.50 ± 0.28% (CARR/HA50 wafer). 306 
Figure S2 (supplementary data) shows the FTIR spectrum (A) and assignment of the main 307 
absorption bands (B) of the raw materials and CARR/HA wafers at different ratios of HA.  308 
CARR/HA10
CARR/HA30 CARR/HA50
CARR
 16 
Table 1: Comparison of physical properties between different composite CARR/HA wafers 309 
 310 
3.3 Swelling studies 311 
Figure 2 showed differences in swelling capacity depending on the proportion of HA. The 312 
percentage swelling increased with time but the total capacity was lower in the presence of HA 313 
which was pronounced after 30 min, where the water uptake was 3528 ± 61% and 1966 ± 27% for 314 
CARR and CARR/HA50 respectively and statistically significant (p < 0.05). The curves show that 315 
after 6 h the maximum swelling was achieved for all the formulations except CARR/HA50, which 316 
continued to absorb water until 24 h. After 6 h, CARR wafers showed a significantly (p < 0.05) 317 
higher swelling capacity compared to CARR/HA30 and CARR/HA50 with a maximum of 3847 ± 318 
30%, whilst increase in HA caused a decrease in the swelling with CARR/HA50 showing a 319 
maximum value of 2867± 143%. After 6 h no significant differences are found in swelling between 320 
CARR and CARR/HA10 wafers. 321 
  
Porosity (%) 
Apparent 
density (mg/cm3) 
Water 
absorption (%) 
Water 
retention (%) 
EWC (%) 
Moisture 
content (%) 
CARR 92.25 ± 4.53 26.78 ± 1.51 3782.7 ± 86.9 96.91 ± 0.53 97.40 ± 0.09 17.00 ± 0.57 
CARR/HA50 85.00 ± 2.62 30.32 ± 1.25 3640.2 ± 39.1 98.88 ± 0.57 97.33 ± 0.03 18.50 ± 0.28 
CARR/HA30 87.95 ± 3.55 29.69 ± 1.75 3394.1 ± 112.5 97.61 ± 1.70 97.04 ± 0.21 17.10 ± 0.44 
CARR/HA10 89.06 ± 2.98 30.55 ± 0.60 3270.7 ± 70.8 95.65 ± 1.33 97.03 ± 0.08 16.73 ± 0.29 
 17 
 322 
Figure 2: Swelling profiles of CARR and CARR/HA wafers (n = 3, ± SD). After 6 h CARR wafers have a significantly 323 
(p < 0.05) higher swelling capacity vs CARR/HA30 and CARR/HA50 while the difference between CARR and 324 
CARR/HA10 was not significant. Moreover, no differences were noted in case of LID and AgNPs loaded wafers. 325 
 326 
 327 
3.4 Mechanical hardness and in vitro mucoadhesive properties. 328 
Figure 3A shows the changes in ‘hardness’ for the wafers with increasing concentration of 329 
HA which suggests increased ‘hardness’ (decreased flexibility), which could affect rate of 330 
hydration, swelling and mucoadhesion performance. Figure 3B shows the adhesion properties of 331 
CARR and composite CARR/HA wafers represented by PAF, WOA and cohesiveness. The CARR 332 
wafers had a higher PAF (0.740 ± 0.070 N) compared to the CARR/HA50 (0.355 ± 0.057 N), with 333 
a decreasing trend proportional to the presence of HA. The same trend was observed for WOA and 334 
cohesiveness. These three parameters are directly influenced by the physicochemical properties of 335 
the wafer such as the pore size distribution and the consequent hydration capacity (Pawar et al., 336 
2014).  337 
 338 
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A) 340 
 341 
 B) 342 
 343 
Figure 3: A) Resistance to deformation (‘hardness’) of CARR or CARR/HA wafers compressed at three different 344 
locations (n = 5, ± SD). B) Adhesion profiles showing PAF, WOA and cohesiveness of CARR and CARR/HA wafers 345 
(n = 5, ± SD). Ordinate definition for the different parameters was reported in the figure legend. 346 
  347 
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3.5 In vitro LID release 348 
The LID release profiles for CARR and CARR/HA wafers (n = 3) are shown in Figure 4, 349 
showing controlled release over 6 h. Wafers with HA appear to release the drug more rapidly 350 
initially, though the differences do not appear marked.  351 
 352 
 353 
Figure 4: In vitro LID cumulative release (n = 3 ± SD) profiles from optimized drug loaded 354 
wafers containing different proportions of CARR/HA. 355 
 356 
 357 
3.6  In vitro cytotoxicity 358 
Figure 5 shows the effect of the wafers on keratinocyte cells with all formulations showing 359 
a good toxicity profile with a not significant reduction in viability in all the samples if compared 360 
with the CARR- BLK wafer. In the range of concentrations studied the presence of both LID and 361 
AgNPs seems not to influence the cells viability if compared to the positive control, triton-x, which 362 
showed less than 10% cell viability (data not shown). Though the results show that there is a time 363 
dependent mortality at 72 h below 90%, this is acceptable because the recommended guidelines 364 
for in vitro cytotoxicity for medical devices and delivery systems such as wound dressings (DIN 365 
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EN ISO 10993-5) specifies that such materials can be deemed non-cytotoxic for ≥70% cell 366 
viability after exposure (Moritz et al., 2014, Cerchiara et al., 2017). Therefore, the results obtained 367 
in the current study show that all the formulated dressings are generally safe. 368 
 369 
Figure 5. Effect of CARR/HA wafers on cells viability of normal adult human primary epidermal keratinocytes. 370 
HaCaT have been seeded at 10,000 cells per well in a 96-well flat-bottomed culture plates and cultured with the 371 
extraction media for 24, 48 and 72 h. Bars represent the mean ± standard deviation of three independent experiments 372 
(n = 3 ± SD). 373 
 374 
3.7 Antibacterial assays 375 
Significant difference (*p < 0.05; **p < 0.01) in the absorbance value at 580 nm was observed 376 
with S. aureus, E. coli and P. aeruginosa after 6 h of incubation for all the samples tested (Figure 377 
6). This activity was strictly related to AgNPs concentration. The activity profile of all the wafers 378 
on P. aeruginosa was quite different compared to the other bacterial species used in this 379 
experiment, since the antimicrobial activity lasted for at least 48 h. Difference in turbidity after 24 380 
h can be clearly visualized from the photograph of the test tubes containing CARR-AgNPs500 381 
(supplementary data, Figure S4). Furthermore, even though some authors have found that LID has 382 
some antibacterial action against E. coli, S. aureus, and P. aeruginosa (Aydin et al., 2001) this 383 
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activity was not noticeable in initial trial observations with starting materials which suggested that 384 
the LID present in the wafers did not show any recordable antibacterial activity. The wafers were 385 
loaded with 10% LID (w/w based on total polymer weight) which was equivalent to 0.2% w/w 386 
and this loading was chosen to be comparable with a high loading commercially available cream. 387 
This dose of LID in our wafers was significantly lower than those tested in Aydin et al, (2001), 388 
(5%, 2% and 1%) in solution, with only the 5 and 2% solutions showing broad antibacterial 389 
activity. In addition, the LID used in the Aydin et al (2001) study was in solution and therefore in 390 
direct immediate contact with the bacteria cells whiles the LID in our wafers will not be released 391 
immediately due to the need for initial wafer hydration and subsequent diffusion from the swollen 392 
dressing into the medium to allow antibacterial inhibition. Therefore we attributed all the 393 
antimicrobial activity to the AgNPs, though future study investigating possible synergistic 394 
antibacterial activity of both LID and AgNPs will be interesting, given the potential to reduce 395 
possible toxicity by using lower doses of AgNPs. 396 
 397 
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 398 
Figure 6: Absorbance values (on ordinate axis) of P. aeruginosa, E. coli S. aureus after 6, 24 and 48 h of incubation 399 
with wafers loaded with different amounts of AgNPs. Significant differences in absorbance in comparison to control 400 
are indicated with asterisks (*p < 0.05; **p < 0.01). Data are means of three independent experiments (n = 3 ± SD). 401 
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4 DISCUSSION 402 
Pain management in wound healing represents a challenge for physicians and nurses faced with 403 
an increased number of patients affected by different pathologies. Wound dressings are the main 404 
devices employed in these therapies and their correct use is an important factor that influences 405 
the therapeutic outcome. The simultaneous delivery of a local anesthetic (LID) and an 406 
antimicrobial agent (AgNPs) directly to the wound site can be an effective way to respectively 407 
target pain itself directly and indirectly on infections, one of the main causes of wound pain due 408 
to prolonging the inflammatory phase. Furthermore, the importance of HA in wound repair and 409 
tissue regeneration is now considered a critical biomaterial affecting wound healing phases 410 
(Frenkel, 2012) and its integration into advanced dressings represents a versatile approach to 411 
promote wound healing that can be easily translated into a clinical setting (Catanzano et al., 412 
2015). 413 
 κ-carrageenan has been employed as films and wafers for wound healing (Boateng et al., 414 
2013; Pawar et al., 2014; Pawar et al., 2013). For our purpose, CARR and composite CARR/HA 415 
wafers with different HA content were successfully prepared by freeze-drying. FT-IR 416 
spectroscopy was used to confirm the absence of chemical interaction between CARR and HA 417 
during the wafer formulation (Figure S2 in supplementary data). No reaction occurred between 418 
CARR and HA as there was no significant new peak observed for the composite wafers, 419 
suggesting that the two polymers were readily compatible within the composite wafer matrix. 420 
The characteristic peak of pure HA appears almost at the same position in the FT-IR spectra of 421 
CARR/HA wafers, despite the changes in peak intensity attributed to different amounts of HA 422 
used. From a microscopic point of view, all the wafers were porous with an interconnecting 423 
network, but micrographs from the SEM shows the effect of HA on the pore shape. CARR/HA 424 
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wafers pores are smaller with reduced depth since the HA partially fills the gaps between the 425 
CARR chains, which also explains the reduction in porosity. This effect of HA on porosity was 426 
also confirmed by evaluating the wafer recovery after deformation at different compression 427 
depths (Supplementary data, Figure S3).  428 
 During wound dressing formulation, pore size and depth should be optimized as they 429 
could significantly affect dressing performance in terms of hydration capacity, adhesion, 430 
swelling and drug release (Kianfar et al., 2014). Furthermore, a uniform and solid porous 431 
structure of crosslinked sponges should “lock” the water molecules and prevent easy runoff of 432 
exudate. Attaining a dry state after lyophilization is essential to reduce molecular mobility and 433 
hence, increased shelf life. Since no product melt-back was observed, the robustness of the 434 
freeze-drying cycle is depicted, with the primary drying stage removing all the loose water. The 435 
residual moisture content was derived from the loss in weight and represent bound water that 436 
remains after the freeze-drying process. The swelling capacity is an essential characteristic, as 437 
CLUs generally produce significant amounts of exudate that should be quickly absorbed and 438 
retained over a prolonged period. The ability to absorb fluids and retain moisture without leaking 439 
is essential for application on suppurating wounds, where high water retention capacity is 440 
required (Boateng et al., 2008). During wound healing, moisture reactive dressings are able to 441 
maintain a moist wound environment whilst at the same time avoiding the accumulation of 442 
excess exudate on the wound, which can slow down wound healing and cause skin maceration 443 
(Boateng & Catanzano, 2015). The water absorption kinetics of the wafers developed in this 444 
study was mainly related to the composition of HA, despite the hydrophilic and polyanionic 445 
characteristics of both polymers. This behavior was recently reported (Catanzano et al., 2017) 446 
and can be attributed to the HA chain stearic hindrance and increased internal micro-viscosity 447 
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within the cross-linked network that opposes the osmotic force, which drives water molecules 448 
into the matrix. This is interesting, as the rate and duration of swelling, determines the ability of 449 
the dressing to control drug release over a prolonged period, without the need for regular 450 
dressing change (King et al., 1991). 451 
 The ideal dressing is required to be tough to allow ease of application without breaking 452 
but should be soft and flexible to avoid possible contact irritation on the wound and the 453 
destruction of newly formed skin tissue (Boateng et al., 2010). The increase in ‘hardness’ with 454 
the increasing HA could affect swelling and mucoadhesion performance as ‘hardness’ is 455 
indicative of wafer density in the internal matrix which affects the rate of water ingress, 456 
hydration, impacting on swelling and adhesion (King et al., 1991; Boateng et al., 2010). 457 
 The use of local anesthetics in wound management is controversial due to their reported 458 
delaying effects on wound healing mainly attributable to a reduction in collagen synthesis 459 
(Chvapil et al., 1979). However, as demonstrated by Drucked et al., local infiltration of LID does 460 
not substantially alter wound healing as they observed no differences in the morphology and 461 
mechanical properties of the wounds (Drucker et al., 1998). Furthermore, LID has a lower 462 
incidence of allergic reactions than the ester-type anesthetics such as procaine and tetracaine 463 
(Popescu & Salcido, 2004). Though solid lipid microparticles (Albertini et al., 2013) or 464 
electrospun scaffolds (Thakur et al., 2008) have been proposed for controlled delivery of LID to 465 
the wound site, they are difficult for large scale production and in clinical settings. The purpose 466 
of this work was the development of a simple, economical but effective advanced multi-467 
functional composite dressing with LID directly dispersed in the polymeric matrix. Drug release 468 
from biodegradable polymeric matrices is strictly correlated to water ingress into the device (Fu 469 
& Kao, 2010). For wound dressings, drug release is driven by the exudate first hydrating the 470 
 26 
polymer to cause swelling, dissolving and releasing the drug by gradual diffusion through the 471 
swollen gel to the wound site. HA caused a significant (p < 0.05) decrease in water uptake but 472 
had minimal influence on LID release. The drug release was sustained up to 6 h in all the 473 
formulations, which implies that the drug release is mainly determined by the CARR, however 474 
HA is still a vital dressing component, given its known wound healing properties. Furthermore, 475 
enough LID was released from all the formulations (about 50%) in the first hour of dissolution 476 
study. This suggests that the dressing could potentially manage pain within the first 60 minutes 477 
of application which is important to quickly relieve the severe acute pain, common in leg ulcers 478 
especially during dressing change, wound cleansing and new dressing application. However, 479 
further in vivo studies are needed to confirm the real pain relieving and wound healing activities 480 
of these dressings 481 
 Keratinocytes are the major cellular component of the epidermis and are directly involved 482 
in re-epithelialization (Pastar et al., 2014) and provide a reliable in vitro model of re-483 
epithelialization phase in wound healing (Sivamani et al., 2007). For the toxicity studies the 484 
higher concentration of AgNPs (750 μg/wafer) was chosen among all the formulations prepared 485 
and the keratinocyte viability was comparable to that achieved with the blank wafer. All 486 
formulations showed a similar viability profile and the addition of both LID and AgNPs in the 487 
range of concentrations studied did not have any effect on cell viability. On the basis of toxicity 488 
data, the AgNPs maximum amount in the hydrogels was fixed at 750 μg/wafer in all the 489 
subsequent experiments. 490 
 Wound colonization by bacteria is common in chronic wounds and in some cases, low 491 
levels of bacteria seems to be beneficial to the wound healing process (Edwards & Harding, 492 
2004). The progression from colonization to infection depends on the bacterial count, host 493 
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immune response, number of different species present, virulence of the organisms and 494 
synergistic interactions between the different species (Edwards & Harding, 2004). AgNPs are 495 
well established as antibacterial and dependent on physicochemical properties of the 496 
nanoparticles, particularly the surface characteristics and particle size. For this study, very small 497 
AgNPs with a narrow size distribution (mean diameter 0.8 nm) and a low polydispersity index 498 
(0.110) were used. Several studies have reported the size dependent activity of AgNPs (Rizello 499 
& Pompa, 2014) with small AgNPs (< 20 nm) inducing stronger bactericidal effect compared to 500 
larger ones due to larger area-to-volume ratio and higher total surface area for membrane 501 
interaction. The antimicrobial properties of AgNPs loaded wafers were tested on the most 502 
common microorganisms present in CLUs (Ramani et al., 1991), and as expected the 503 
antibacterial activity was strictly related to AgNPs concentration. The AgNP loaded wafers were 504 
able to kill all the bacteria tested after 6 h of contact time while a different antimicrobial activity 505 
was detected between Gram-positive and Gram-negative bacteria after 24 and 48 h, possibly due 506 
the structural differences between the two classes. However, the Gram-negative E. coli showed a 507 
lower susceptibility after 24 and 48h to CARR-AgNPs wafers than the other Gram-negative 508 
strain (P. aeruginosa). Apart from the composition of the outer cell layers, AgNPs antibacterial 509 
activity may also be related to the features of the individual bacterial species, and some strain-510 
specific variation in MICs and MBCs was observed for E. coli (Ruparelia et al., 2008). 511 
 512 
5 CONCLUSIONS 513 
In the current study, we hypothesized that composite CARR/HA based wafers, loaded with LID 514 
and AgNPs could potentially address pain associated with CLUs as well as deal with infection 515 
which is one of the main causes of chronic inflammatory pain and this was confirmed from the 516 
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results. We have demonstrated how lyophilized wafers can be designed to obtain a simple, 517 
economical but effective multi-targeted composite wound dressing useful for pain management 518 
in CLUs. CARR/HA wafers with various HA contents showed a porous nature with an 519 
interconnecting network and pore size related to the amount of HA which was also confirmed by 520 
texture analysis and swelling studies. Texture analysis also confirmed the good handling 521 
properties that together with ease of preparation are essential to provide a rapid and effective 522 
treatment for CLUs in hospitalized patients. The fast drug release and the effective antimicrobial 523 
activity confirm that the association of an analgesic drug (LID) with an antimicrobial compound 524 
(AgNPs) could further increase the effectiveness of this dressing in pain and infection 525 
management. Finally, CARR/HA wafers seems to be a very promising system for the treatment 526 
of wound pain, however, further studies are needed to evaluate the in vivo wound healing 527 
activities of the dressings.  528 
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